focus -WSS

focus

author：fashion 2025-09-28 01:37:54 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： PBM executives asked to testify by House panel

focus

WSS

Sen. Paul opposes bill to ban Chinese biotechs

UnitedHealth quietly bought dozens of outpatient centers

As billionaires fund anti

Has Bernie Sanders reached the limit of his pharma bullying effort?

Chemotherapy before breast cancer surgery might fuel metastasis

As health system earnings go up, health insurance stocks go down

hotspot

focus

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AltruBio raises $225 million to develop ulcerative colitis drug

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

The cancer drug shortage isn’t new — and neither are the solutions

Sen. Paul opposes bill to ban Chinese biotechs

What does generative AI mean for health care? We asked experts

AltruBio raises $225 million to develop ulcerative colitis drug

Sports medicine is finally prioritizing gender equality

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Wikipedia

The drug industry has found itself all alone in Washington

With psoriasis trial ahead, Alumis raises $259 million

Change Healthcare cyberattack prompts Medicare loan program

Deliver public health messages at the right time

AltruBio raises $225 million to develop ulcerative colitis drug

Headspace, Meta partner to launch VR meditation app for Quest

focus

hotspot

hotspot

leisure time